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As a prophylactic cancer vaccine, human amniotic membrane epithelial cells (hAECs) conferred effective protection in a murine
model of colon cancer. The immunized mice mounted strong cross-protective CTL and antibody responses. Tumor burden was
significantly reduced in tumor-bearing mice after immunization with hAECs. Placental cancer immunotherapy could be a prom-
ising approach for primary prevention of cancer. In spite of being the star of therapeutic strategies for cancer treatment, the
results of immunotherapeutic approaches are still far from expectations. In this regard, primary prevention of cancer using
prophylactic cancer vaccines has gained considerable attention. The immunologic similarities between cancer development
and placentation have helped researchers to unravel molecular mechanisms responsible for carcinogenesis and to take advan-
tage of stem cells from reproductive organs to elicit robust anti-cancer immune responses. Here, we showed that vaccination
of mice with human amniotic membrane epithelial cells (hAECs) conferred effective protection against colon cancer and led to
expansion of systemic and splenic cytotoxic T cell population and induction of cross-protective cytotoxic responses against
tumor cells. Vaccinated mice mounted tumor-specific Th1 responses and produced cross-reactive antibodies against cell
surface markers of cancer cells. Tumor burden was also significantly reduced in tumor-bearing mice immunized with hAECs.
Our findings pave the way for potential future application of hAECs as an effective prophylactic cancer vaccine.
Introduction
Malignancies are one of the main leading causes of death in
human societies. Besides partial effectiveness, toxic side
effects particularly on non-cancerous cells have always been
an important concern in traditional medical treatments of
cancer.1 As a result, development of new effective therapeutic
methods with lesser unwanted side effects is essential. There
are numerous and undeniable evidence showing the involve-
ment of immune system in recognition and destruction of
cancer cells. In this context, immunotherapeutic approaches
have drawn scientist’s attention in the past two decades and
have been a signiﬁcant milestone for treatment of different
types of cancer.2 The most important issue in cancer immu-
notherapy is the selection of an appropriate target antigen
capable of eliciting strong anti-tumor immune responses. In
this regard, oncofetal antigens were shown to possess many
desirable characteristics to be targeted in cancers.3
The immunologic similarities between cancer and preg-
nancy were proposed as early as 1884. According to Savory
“. . .before we shall ever be able to answer the question of
why or how tumors form . . . we must be able to solve the
problem of normal growth and development”.4 Then, Schone
reported that vaccination of mice with fetal tissues lead to
the rejection of transplanted tumors.5 Subsequently, experi-
ments indicated that vaccination of animals with embryonic
materials provided surprisingly strong cellular and humoral
immunity against implantable tumors, carcinogenic viruses or
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chemical carcinogens and supported the idea that anti-tumor
immunity arise from the presence of antigens common in
fetal tissue and tumor cells.6 Similar observations were
reported by other investigators.7,8
To unravel molecular mechanisms of such beneﬁcial
effects, several investigations have scrupulously identiﬁed sev-
eral candidate antigens common in embryonic tissues and
cancer including carcinoembryonic antigen (CEA),9 prostate-
speciﬁc antigen (PSA),10 survivin,11 Ki-1 (CD30),12 placental
alkaline phosphatase (PLAP),13 RCAS1,14 to list a few.
After a rather long period of scientiﬁc gap probably due
to technical limitations, the association between pregnancy
and cancer was again proposed in a more fascinating form:
the cancer stem cell theory.15 Accordingly, cancer stem cells
were shown to possess many similar characters such as anti-
gens and surface markers in common with normal embry-
onic stem cells (ESCs) which are not expressed in normal
tissues and play an important role in metastasis, angiogenesis
and chemo resistance.16 After then, several attempts were
made to show protective effects of vaccination with ESCs on
cancer development and propagation. Li et al. showed that
vaccination of mice with human ESC cell line, H9, generated
signiﬁcant cellular and humoral immune responses against
CT26 colon carcinoma .17 Then, Dong et al. demonstrated
that C57BL/6 mice vaccinated with ESC were cross-
protectively immunized against the establishment and expan-
sion of lung cancer.18 These ﬁndings were further supported
by additional studies showing that vaccination with ESCs
successfully induced activation of anti-tumor immunity.19,20
Despite these promising results, ethical problems and the
concerns on development of cancer with embryo-derived
stem cells have always been the main limitation in using
ESCs for clinical application and this may explain why vacci-
nation with fetal materials for tumor immunity has never
gone beyond animal models.
Placenta is a unique tissue in the body that exists for a
very limited period of pregnancy and provides an exceptional
microenvironment capable of controlling invasion of tropho-
blast cells. Notably, as we and others reported recently, vital
parameters of cancer cells are modulated by placental factors
and microenvironment21 and that placenta expresses such
novel markers as PLAC1 (placenta-speciﬁc 1) shared by
many cancer cell types.22,23 It also hosts a collection of cells
with stem cell properties.24 More importantly, placental-
derived cells and proteins could effectively hinder the out-
growth of cancer cells in murine models.25,26 One such cell
type with epithelial origin is human amniotic epithelial cells
(hAECs). Similarity of hAECs to embryonic stem cells has
been demonstrated by earlier reports.27 Based on the fact that
many human cancers are originated from epithelial layers
and that hAECs conceptually do not have aforesaid concerns
associated with the application of human ESCs due to lack of
telomerase activity,24 we were about to examine whether
immunization with hAECs could potentially stimulate anti-
tumor immune responses and prevent cancer development in
a murine model of colon adenocarcinoma.
Materials and Methods
Animals and cell line
Female 6–8 weeks BALB/c mice, two month old White New
Zealand rabbits, BALB/c adenocarcinoma cell lines, CT26
(colon), Renca (kidney) and 4T1 (breast) and C57BL/6 mela-
noma cell line, B16F10, were obtained from the Pasteur Insti-
tute of Iran (Iran, Tehran). Cells were cultured in RPMI-
1640 supplemented with 10% fetal bovine serum (FBS) and
antibiotics and incubated in a CO2 incubator, 378C. Animals
were kept in a standard condition with a 12-hr light–dark
cycle and fed ad libitum. The animal experiments were car-
ried out using a protocol approved by the Animal Care Com-
mittee of Shahid Beheshti University of Medical Sciences and
Avicenna Research Institute (Iran, Tehran).
Reagents and antibodies
List of reagents and antibodies used in our study has been
provided in Supporting Information.
Multi-lineage differentiation of hAECs
Multi-lineage differentiation potential of hAECs was exam-
ined according to the protocols we published recently.28–30
Detailed information on osteogenic, chondrogenic and adipo-
genic differentiation of hAECs has been provided in Support-
ing Information.
Isolation and immunophenotyping of amniotic epithelial
cells
All procedures conducted on human materials were approved
by the ethical committee of Avicenna Research Institute and
Shahid Beheshti University of Medical Sciences and all
What’s new?
Cancer stem cells are immunologically similar to embryonic stem cells (ESCs). In particular, both express antigens that are
elevated in the presence of cancer. Ethical issues surrounding the use of ESCs have motivated the search for additional cell
types with similar stem properties. Our study shows, in a murine model of colon cancer, that placenta-derived human amniotic
membrane epithelial cells (hAECs) can elicit a strong anticancer immune response, effectively protecting animals against colon
tumor development. In mice with tumors, hAEC treatment lessened tumor burden significantly. The findings suggest that pla-
cental cancer immunotherapy is a promising approach for cancer prevention.
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participants signed a written consent form before enrolment to
our study. hAECs were obtained from uncomplicated term
pregnancies delivered by elective cesarean from 4 healthy
women aged 22 to 32 years and characterized using ﬂow
cytometry in accordance with the protocols we described previ-
ously.31 Expression of cytokeratin, CD9, CD10, CD29, CD73,
CD34, CD38, CD44, CD105, CD133, HLA-I, HLA DR, HLA-
G, SSEA-4, STRO-1 and OCT-4 was assessed by ﬂow
cytometry.
Immunization and tumor challenge
Effectiveness of hAECs immunization on induction of anti-
tumor responses was investigated in two independent preventive
and therapeutic approaches. To study the preventive effect of
immunization, 48 female BALB/c mice were randomly divided
into three groups of n5 16: hAECs vaccine group, CT26 vaccine
group (positive control group) and a PBS control group. First
and second groups of mice were immunized subcutaneously
with 1 3 106 live hAECs and 5 3 105 live 100 Gy gamma-
irradiated CT26 tumor cells in 100 ml PBS, respectively, three
times at one week interval. In parallel, control group received
100 ml PBS subcutaneously. One week after the third vaccina-
tion, eight mice from each group were sacriﬁced and evaluated
for their anti-tumor responses, while another eight mice were
challenged subcutaneously with 5 3 105 live CT26 cells. To
examine potential protective effect of hAECs vaccination against
other murine-derived cancer cells, hAECs-vaccinated BALB/c
(n5 10) and C57BL/6 mice (n5 10) were challenged as above
with 1 3 105 live 4T1 and B16F10 cells, respectively, and tumor
growth and survival were monitored and compared to the con-
trol group which received PBS. In the therapeutic approach, the
treatment group (n5 8) received three hAECs immunizations
(with one week interval) eight days after inoculation of CT26,
when the touchable tumor masses had developed. Likewise, the
control group (n5 8) received subcutaneously three PBS injec-
tions eight days after CT26 inoculation.
Evaluation of tumor size
Tumor growth was monitored every 3 days using digital cali-
pers to measure length (a, mm) in the direction of the imagi-
nary longitude and the width in the direction of the latitude
(b, mm). The tumor area (a 3 b, mm2) was then calculated.
Moreover, mice were followed for their general health symp-
toms: behavior, feeding and body weight. The mice were
euthanized when one dimension of a tumor reached 15 mm
or the tumor area of >225 mm2 was observed. The primary
tumor was also removed and weighed after the mice were
sacriﬁced. According to the Animal Care Committee guide-
lines and to avoid pain and suffering, survival experiments
were not performed on tumor bearing mice.
Evaluation of T cell frequency
One week after the third vaccination, peripheral blood and sple-
nocytes were obtained from mice and the percentage of
CD31CD41/CD81 T cells was determined by ﬂow cytometry.
For peripheral blood immunophenotyping,100 ll Sodium
Citrate-anticoagulated blood was mixed and incubated in the
dark with 20 ll of each monoclonal antibody at 48C for 20
min. Red blood cells were then lysed by RBC lysis kit according
to the manufacturer’s recommendation and percentage of posi-
tive cell was determined by ﬂow cytometry. In parallel, spleens
were excised under sterile condition, splenocytes were separated
by perfusion and grinding of spleens and mononuclear cells
(MNCs) were isolated by Ficoll density gradient before immu-
nopheotyping. Viability of the isolated cells was tested by try-
pan blue exclusion test and was always shown to be >95%.
One million cells from each spleen were then stained as above.
Measurement of cytotoxic T lymphocyte responses
To evaluate cross-reactive cytotoxic T lymphocyte (CTL)
responses against tumor cells after vaccination with hAECs,
lactate dehydrogenase (LDH) assay was employed. Brieﬂy,
one week after the third immunization, spleen MNCs were
isolated as above and washed twice with RPMI-1640. Spleno-
cytes, as effector cells, were seeded into the round-button 96-
well culture plates in 50 ml assay medium (RPMI1 1%
bovine serum albumin (BSA)) at different numbers (1.25, 2.5,
5 3105 cells). After a period of 12 hr, target cells (CT26 or
hAECs) were added (1 3 104 cells/well) to the wells in tripli-
cate in 70 ml RPMI-1640 to achieve target/effectors ratios of
1:50, 1:25 and 1:12.5, respectively; and plates were then incu-
bated for 6 hr in a 378C, 5% CO2 incubator. The target and
effector cells cultured alone served as spontaneous LDH
release control (low controls). For the maximum LDH release
(high control), 2% Triton X-100 was added to the wells con-
taining target cells. The percentage of cytotoxicity was deter-
mined based on the following formula:
Cytotoxicity ð%Þ5 ð½ðeffector target cell mix2 effector cell controlÞ
2 low control=ðhigh control2 low controlÞ3100:
Cytokine measurement
One week after the third immunization, splenocytes were
obtained as described above and were co-cultured (1 3 106)
with 1 3 105 mitomycin-inactivated target cells in 24-well
culture plates in a ﬁnal volume of 1 ml complete medium(-
RPMI-1640 supplemented with 12% FBS) per well. After 48
hr, supernatant was collected and tested for the levels of IL-
10, IL-4 and IFN-g by ELISA sets as per manufacturer’s
instructions. The optical densities at 570 and 450 nm (as a
reference wavelength) were recorded by an ELISA reader
(Anthos, Austria) and concentration of each cytokine was
determined using the corresponding standard curve. The
minimal detection limits for IL-10, IFN-g and IL-4 were
31.3, 31.3 and 7.3 pg/ml, respectively.
Analysis of cross-reactive antibody responses by
immunofluorescent staining and flow cytometry
In order to investigate cross-reactive antibody responses
against CT26 cells in mice receiving hAECs, blood sample
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was collected via cardiac puncture one week after the third
immunization and serum was separated. CT26 and hAECs
cells (as positive control) were harvested, cytospinned and
ﬁxed with ice cold acetone for 2 min. Cells were then washed
twice with PBS1 0.5% BSA each for 5 min. The cells were
incubated for 30 min at room temperature (RT) with PBS
containing 5% sheep serum and 2.5% BSA to block non-
speciﬁc reactions followed by three washing steps with PBS.
Afterward, the cells were incubated with 1:200 dilution of
hyper immune mouse sera for 90 min. Negative reagent con-
trol slides received non-immune mouse serum with the same
dilution. After being washed with PBS, cells were incubated
with FITC-conjugated sheep anti-mouse Ig (diluted 1:50) at
RT for 45 min and washed with PBS as above. The nuclei
were stained with DAPI (0.5 mg/ml). Finally, the cells were
examined under ﬂuorescence microscope (Olympus BX51,
Japan) equipped with DP71 CCD camera. As control, reactiv-
ity of sera from hAECs-immunized BALB/c mice with 4T1
and Renca and that of hAECs-immunized C57BL/6 sera with
B16F10 cells were tested as described above. To examine
whether or not induction of cross- reactive antibody
responses is species-speciﬁc, New Zealand white rabbits were
immunized subcutaneously with live hAECs four times with
two week interval and reactivity of hyper immune sera was
then tested on hAECs and CT26 cells as above. Indeed, reac-
tivity of rabbit polyclonal anti-hAECs antibody was also
tested by ﬂow cytometry. To this end, hAECs and CT26 cells
were washed with PBS containing 1% FBS (PBS-FBS) and
incubated with 1:200 dilution of hAECs-immunized rabbit
sera for 30 min on ice. After washing with PBS-FBS, cells
were incubated with FITC-labeled sheep anti-rabbit Ig for 20
min and analyzed by ﬂow cytometry as above. Cells incu-
bated with the same dilution of pre-immune rabbit serum
were used as control.
Statistical Analysis
The numerical values of the results were presented as
mean6 SEM. Comparisons between groups were done by
Kruskal Wallis and Mann-whitney. P values <0.05 were con-
sidered to be signiﬁcant. Statistical analysis was performed
using GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla,
CA, http://www.graphpad.com) software.
Results
hAECs expressed markers of mesenchymal and embryonic
origin
About 80–130 3106 hAECs were isolated from each placenta
unit with high purity as judged by assessment of cytokeratin
expression ( 90%) .Trypan blue dye exclusion test revealed
a viability of >95%. These cells appeared as ﬂat round cells
with abundant cytoplasm and high cytoplasm: nuclear ratio.
Immunophenotyping of hAECs was performed using ﬂow
cytometry. Accordingly, hAECs were positive for cytokeratin,
CD9, CD10, CD29, CD73, CD105, HLA-I, HLA-G, STRO-1,
SSEA-4 and OCT-4 while they were negative for HLA-II,
CD34, CD38, CD44 and CD133 (Fig.1a).
hAECs showed multi-lineage differentiation potential
Nodule-like structures with calcium deposits were formed
with a strong positive staining for Alizarin red (Fig.1bb).
Moreover, Alcian blue staining showed abundant accumula-
tion of proteoglycan in differentiated cells into chondrocytes
(Fig.1bd). In contrast to differentiated cells, undifferentiated
cells were negative in both staining procedures (Fig.1ba and
bc). Despite several attempts for adipogenic differentiation of
hAECs, they displayed the absence or very faint staining for
lipids (Fig.1bf).
Vaccination with hAECs conferred protection in a murine
model of colon cancer
BALB/c mice were immunized with irradiated CT26 cells,
live hAECs, or PBS and challenged with living CT26 cells
thereafter (Fig. 2a). The rate of tumor growth in terms of
size and weight was then followed closely until 35 days post
tumor inoculation. Remarkably, vaccination with both CT26
and hAECs resulted in complete inhibition of tumor develop-
ment in all vaccinated mice compared to the control group
(***p < 0.001) (Fig. 2b and 2c). However, in control mice
receiving PBS, tumors were developed and increased in sized
steadily (Fig. 2d). We also tested the potential of hAECs vac-
cination in protecting mice against breast (4T1) and mela-
noma (B16F10) cancer cells. We found that hAECs
vaccination did not confer protection against 4T1 cells in
terms of survival rate (Fig. 2e) or tumor growth (Fig. 2f).
However, Mice vaccinated with hAECs were signiﬁcantly
protected against B16F10 challenge (Fig. 2g). Indeed, hAECs
vaccination signiﬁcantly delayed tumor development and
reduced tumor weight in vaccinated C57BL/6 mice (Fig. 2h)
(p < 0.0001).
Vaccination with hAECs led to expansion of systemic and
splenic cytotoxic T cell population
To determine whether hAECs immunization resulted in
expansion of CD41 and CD81 T lymphocytes, we measured
their frequency in peripheral blood (Fig. 3a and 3b) and
spleen (Fig. 3a and 3c) of vaccinated mice. Our data notably
demonstrated that the percentages of peripheral blood and
splenic T cells (CD31) in both hAECs and CT26 vaccine
groups were signiﬁcantly higher compared to those in the
control group (p<0.01–0.001). Of note, hAECs-vaccinated
mice had higher frequency of peripheral and splenic CD41 T
(p< 0.01–0.001) and CD81 cells (p< 0.05–0.001) compared
to the control group. CT26-immunized mice showed the sim-
ilar trend of T cell expansion, although the level of splenic T
cell expansion was even higher in this group compared to
hAECs-immunized mice (p<0.01).
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Vaccination with hAECs-induced tumor-specific, cross-
protective cellular immunity against CT26 cells
The data depicted in Figure 3d indicate that splenocytes from
both CT26 and hAECs vaccine groups showed strong CTL
activity against hAECs at all target: effector (T:E) ratios
(p<0.01–p<0.001). In parallel, splenocytes from hAECs-
vaccinated mice exhibited strong CTL activity against CT26
cells at all T:E ratios (p<0.001), whereas those from control
mice did not show cytotoxicity. As expected, mice receiving
CT26 cells as vaccine showed very strong CTL activity
against CT26 cells which were signiﬁcantly higher compared
to both control and hAECs vaccine group (p<0.05–
p<0.001)(Fig. 3e).
Immunization with hAECs significantly increased IFN-c
production in response to CT26 challenge
In order to further investigate the immune mechanism
underlying anti-tumor immunity in hAECs-vaccinated mice,
the levels of interleukin (IL)-4 (Fig. 3f), IFN-g (Fig. 3g) and
IL-10 (Fig. 3h) in culture supernatant of splenocytes stimu-
lated with either hAECs or CT26 cells were measured. The
results showed that immunization with hAECs cells induced
a mixed cytokine proﬁle in splenic cells. The level of IFN-g
increased signiﬁcantly after stimulation with either hAECs or
CT26 (p<0.01). The same trend was also observed in mice
vaccinated with CT26 (p<0.01–0.001). Mice vaccinated with
CT26 produced even more IFN-g compared to those vacci-
nated with hAECs (p<0.01). Although hAEC- or CT26-
vaccinated mice produced higher amounts of IL-4 after stim-
ulation with immunizing cells compared to the PBS group
(p<0.05–0.01), stimulation of splenocytes with hAECs or
CT26 in hAEC-vaccinated mice resulted in a signiﬁcantly
lower IL-4 production compared to the cells remained unsti-
mulated (p<0.05). In parallel, spleen cells of hAECs- or
CT26-vaccinated mice increased IL-10 production after stim-
ulation with either hAECs or CT26 (p<0.01–0.001). Non-
stimulated splenocytes of hAECs- or CT26-vaccinated mice
also showed higher tendency to produce IL-4, IL-10 and
IFN-g compared to those from PBS group (p<0.05–0.001).
hAECs or CT26 cells when cultured alone produced no
detectable levels of cytokines (data not shown).
Cross-reactive antibodies were generated against CT26
cells after vaccination with hAECs
Our results clearly showed that sera from the control group
mice reacted neither with hAECs nor CT26. Sera from
hAECs- and CT26-vaccinated mice sharply cross-reacted
with CT26, and hAECs cells, respectively. Interestingly, sera
from hAECs-vaccinated mice recognized antigens in CT26
cells which were predominantly located at cell surface. As
Figure 1. hAECs exhibit multilineage differentiation potential and a mixed mesenchymal and embryonic phenotype. (a) Expression of
markers associated with mesenchymal and embryonic origin was assessed by flow cytometry. The results are representative of three inde-
pendent experiments. In each graph, open and filled histograms represent test and isotype-matched control antibodies, respectively. (b)
Freshly-isolated human amniotic membrane epithelial cells were induced to differentiate toward osteocytes, chondrocytes and adipocyte
and degree of differentiation was verified by Alizarin red, Alcian blue and Oil red stainings, respectively. [Color figure can be viewed at
wileyonlinelibrary.com]
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Figure 2. Prophylactic vaccination with hAECs confers protection against murine colon carcinoma. (a) Vaccination Scheme: PBS, 13 106 hAECs, or 5
3 105 irradiated murine colon cancer cell line,CT26, was injected subcutaneously into BALB/c mice (n58) in phosphate buffered saline three times
at one week interval. Mice were challenged seven days after the last vaccination with 53 105 wild type CT26 cells. (b) Tumor volumes were moni-
tored regularly and calculated by measuring tumor dimensions with digital calipers. (c) Final tumor weights were measured on the excised tumors at
the end of the experiment. (d) Immunization with hAECs or inactivated CT26 cells inhibited tumor growth. Indeed, hAECs-vaccinated BALB/c (n510)
and C57BL/6 (n510) mice were challenged with 13 105 4T1 and B16F10 cells, respectively, as above. hAECs vaccination did not confer protection
against 4T1 cells in terms of survival rate (e) or tumor growth (f). However, Mice vaccinated with hAECs were significantly protected against B16F10
challenge (g). hAECs vaccination significantly delayed tumor development and reduced tumor weight in vaccinated C57BL/6 mice (h) (p< 0.0001).
Error bars denote mean6 SEM. Asterisks (*) indicate statistical significant differences (*p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001). hAECs:
human amniotic epithelial cells, PBS: Phosphate-buffered saline, NG: No growth. [Color figure can be viewed at wileyonlinelibrary.com]
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Figure 3. Vaccination with hAECs augments cross-reactive cellular immunity and CTL responses against murine colon carcinoma. Gating strategy
of blood and spleen immune cells has been shown (a). Prophylactic vaccination with hAECs induced a significant proliferation of CD41 and CD81T
lymphocytes in the peripheral blood (b) and spleen (c) of vaccinated mice compared to the control group (n58). The potential of hAECs vaccina-
tion to induce CTL responses was tested by LDH cytotoxicity assay using spelenocyte of vaccinated mice as effector cells and hAECs (d) or CT26
cells (e) as targets. The percentage of specific lysis was measured at different target: effector (T:E) ratios. Vaccination with hAECs cells induced
cross-reactive CTL responses against CT26 cells at all T:E ratios tested and vice versa. One week after the last prophylactic vaccination, the levels
of IL-4 (F), IFN-g (g) and IL-10 (h) were measured in culture supernatants of spelenocytes stimulated with either hAECs or mitomycin-inactivated
CT26using ELISA. In some wells, cells remained unstimulated. Error bars denote mean6SEM. Asterisks (*) indicate statistical significant differ-
ences (*p< 0.05, **p< 0.01, ***p< 0.001). hAECs: human amniotic epithelial cells, PBS: Phosphate-buffered saline, PV: Prophylactic vaccine.
[Color figure can be viewed at wileyonlinelibrary.com]
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Figure 4. Immunization with hAECs generate cross-reactive antibodies against CT26 cells. (a) Mice (n58) were immunized with either
hAECs or CT26 cells and immune reactivity of sera from each group was tested against both CT26 and hAECs. hAECs-induced antibodies
strongly recognized cross-reactive molecules in CT26 cells which were mostly localized to cell membrane. Similar pattern was also observed
when sera of CT26-vaccinated mice were applied on hAECs cells. As positive control, sera from each vaccine group were separately tested
against immunizing cells and the results were shown always to be positive. (b) Sera from rabbits immunized with hAECs also showed
strong reactivity with CT26 and immunizing cells with cell surface staining pattern. (c) Flow cytometric analysis of sera from hAECs-
immunized rabbits also showed that antibodies directed against hAECs could efficiently recognize native cell surface antigen(s) in CT26
cells. (d) Immunofluorescent staining of 4T1 and Renca cells with sera from hAECs-immunized mice showed weak reactivity in a small pro-
portion of cells. (e) No cross-reactive antibodies were found against B16F10 cells in sera of hAECs-vaccinated C56BL/6 mice, while a strong
immunoreactivity, predominantly localized to the cell surface markers, was observed when sera from hAECs hyper immune sera of C56BL/6
mice were tested against hAECs cells as positive control. Cell nuclei were stained with DAPI. NC: Negative control.
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positive control, sera from each vaccine group were sepa-
rately tested against immunizing cells and the results were
shown always to be positive (Fig. 4a). In line with the results
obtained from hAECs-immunized mice, sera from rabbits
immunized with hAECs showed strong positive reaction with
both immunizing cells and also with CT26 cell line which was
predominantly localized to cell membrane (Fig. 4b). These results
were further validated by ﬂow cytometric analysis of sera from
hAECs-immunized rabbits. The results clearly showed that anti-
bodies directed against hAECs could efﬁciently recognize native
cell surface antigen(s) in CT26 cells (Fig. 4c). To rule out the
possibility that production of cross-reactive antibodies against
CT26 after immunization of mice with hAECs is not due to the
xenogeneic response, or resulted from probable FCS contamina-
tion during immunization, hyper immune BALB/c mice sera
against hAECs were also tested for reactivity with other mouse-
derived cancer cell lines, 4T1 and Renca. As depicted in Figure
4d, most of 4T1 and Renca cells failed to react with anti-hAECs
sera. However, a small proportion of cells reacted with anti-
hAECs sera, although the signal was comparatively weaker than
those obtained with CT26 cells. In parallel, reactivity of hAECs
hyper immune C56BL/6 mice with B16F10 cells was also tested.
The results showed no antibody reactivity against B16F10 cells
in sera of C56BL/6 mice immunized with hAECs, while a strong
immunoreactivity, predominantly localized to the cell surface
markers, was observed when sera from hAECs hyperimmune
sera of C56BL/6 mice were tested against hAECs cells as positive
control (Fig. 4e).
hAECs immunization exerted therapeutic effect after tumor
establishment
To determine whether treatment with hAECs could suppress
tumor progression, tumor-bearing mice received three series
of hAECs immunization one week after inoculation of CT26
cells (Fig. 5a) and tumor growth was monitored every 3 days
(Fig. 5b). Of note, tumor growth was signiﬁcantly retarded
between 13–21 days post tumor inoculation in mice receiving
hAECs compared to the control group. After sacriﬁcing the
mice, tumors were removed and average tumor weight was
measured. Likewise, tumor weight was signiﬁcantly lower in
mice receiving hAECs compared to the PBS-treated control
mice (p<0.05). (Fig. 5c and 5d).
Figure 5. Treatment with hAECs reduces tumor burden in murine colon carcinoma. (a) Immunization schedule: Eight days after inoculation
with CT26, when palpable tumor mass was developed, treatment group (n58) received three hAECs immunization subcutaneously at one
week interval, while control group (n58) received PBS. Tumor volume (b) was monitored regularly over the experimental period. (c) Final
tumor weight of the excised tumors was measured at the end of the experiment. (d) Immunization of tumor-bearing mice significantly
reduced tumor size. Error bars denote mean6 SEM. Asterisks (*) indicate statistical significant differences (*p < 0.05, **p < 0.01,
***p < 0.001). hAECs: human amniotic epithelial cells, PBS: Phosphate-buffered saline, TV: Therapeutic vaccine. [Color figure can be
viewed at wileyonlinelibrary.com]
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Figure 6. Treatment with hAECs increases Th1 immunity and CD81 T cell frequency but not CTL activity. Immunization of tumor-bearing mice with
hAECs induced a significantly higher proliferation of T and CD81T lymphocytes in the peripheral blood (a) and spleen (b) of mice compared to the
control group (n58). CTL activity of splenocytes from hAECs-treated mice was measured by LDH cytotoxicity assay against hAECs (c) and CT26
cells (d). The percentage of specific lyses was measured for different targets: effectors (T:E) ratios. Immunization with hAECs induced significant
specific CTL activity against the same cells at 1:50 and 1:25 T:E ratios, while exerted no significant CTL activity against CT26 cells. One week after
the last prophylactic vaccination, the levels of IL-4 (e), IFN-g (F) and IL-10 (g) was measured in culture supernatants of spelenocytes stimulated
with either hAECs or mitomycin-inactivated CT26using ELISA. Treatment with hAECs caused a significant increase of IFN-g producing cells, while
decreased IL-10 production level in response to CT26 stimulation. Error bars denote mean6SEM. Asterisks (*) indicate statistical significant differ-
ences (*p < 0.05, **p < 0.01, ***p < 0.001). hAECs: human amniotic epithelial cells, PBS: Phosphate-buffered saline, TV: Therapeutic vaccine.
[Color figure can be viewed at wileyonlinelibrary.com]
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Treatment with hAECs augmented the expansion of
peripheral blood and splenic CD81 T cells
The percentages of CD31 T cells in general and CD81 T
lymphocytes in particular in peripheral blood (Fig. 6a) and
spleen (Fig. 6b) of mice treated with hAECs were signiﬁcantly
superior to that of the control group (p<0.05–p<0.001). The
percentage of CD41 T cells in peripheral blood and spleen of
vaccinated mice was also increased signiﬁcantly compared to
the control group (p<0.01–p<0.001).
Treatment with hAECs did not induce significant tumor-
specific CTL responses
As expected, injection of hAECs to tumor-bearing mice
induced a signiﬁcant speciﬁc cellular immunity against hAEC
target cells compared to the control group (Fig. 6c). However,
this treatment did not induce a signiﬁcant increase in CTL
responses against CT26 cells compared to the control group
(Fig. 6d). In contrast to the mice receiving PBS as vaccine
(Fig. 3c and 3d), splenocytes from PBS-treated tumor-bearing
mice group exhibited speciﬁc lysis against hAECs and CT26
target cells (Fig. 6c and 6d).
Treatment with hAECs potentiated Th1 responses
Our results showed that treatment with hAECs caused a sig-
niﬁcant increase in IFN-g- producing cells in the spleen of
tumor-bearing mice (p<0.05), while such treatment resulted
in a decreased IL-10 production level compared to the PBS
group. Production of IL-4 was not affected by hAECs treat-
ment (Fig. 6e–6g).
Discussion
One of the most promising, yet challenging, modalities for
cancer treatment is to mobilize the immune system to com-
bat against malignancy. In this context, targeting tumors by
different arms of the immune system has been the focus of
many basic and clinical researches for over a century.2
Very earlier than introduction of conventional cancer
immunotherapeutic strategies employing monoclonal anti-
bodies and adaptive cellular therapy, similarities between can-
cer and embryonic tissues were noticed. Several studies
clearly corroborated that cancer and embryonic cells have
many antigens in common so that immunization of animals
with embryonic tissues could induce effective anti-tumor
responses.32 A large proportion of vaccine trials conducted so
far for cancer immunotherapy have been based on such
embryonic antigens as carcinoembryonic antigen,33 cancer/
testes antigens33 and a-fetoprotein,34 to list a few. However,
it is very unlikely that monovalent cancer vaccines employing
a single antigen could enlist effective anti-tumor immunity
mainly because of the fast emergence of diverse immune
escape mechanisms by the tumor cells.35,36 Interestingly,
extensive similarities in markers expressed by embryonic and
cancer stem cells prompted the researchers to take advantage
of cross-protective immune responses induced by ESCs
immunization for cancer treatment. Li et al. showed the
potential of human ESCs to efﬁciently immunize against
murine colon cancer.17These ﬁndings were further supported
by the experiments from other investigators showing that
vaccination with human ESCs lead to robust immune activa-
tion against malignant colon, lung and ovarian cancers and
effective suppression of proliferation of cancer cells.18–20
However, due to the ethical problems and fear of creating
teratoma because of the telomerase activity in ESCs, their
utility in cancer immunotherapy is subjected to a serious
concern.
Here, we examined potential of hAECs for being applied
as preventive and therapeutic cancer vaccine in a mouse
model of colon adenocarcinoma. We ﬁrst investigated stem
cell marker signature of hAECs and showed in line with
what reported earlier31,37 that they express well-deﬁned
human mesenchymal stem cell markers (CD9, CD10, CD29,
CD73, CD105), as well as the embryonic stem-cell markers,
Oct-4, SSEA-4 and STRO-1. Their stemness was further con-
ﬁrmed by osteogenic and chondrogenic differentiation poten-
tial. Adipogenic potential of isolated hAECs was also tested.
In line with Diaz-Prado et al.38 hAECs displayed the absence
or very faint staining for lipids.
We next showed for the ﬁrst time that mice immunized
with hAECs resisted tumor induction with highly tumori-
genic CT26 colon cancer cell line. In fact, none of the mice
vaccinated with hAECs developed tumor till the end of
Experiment (35 d post-inoculation) despite injection of CT26
cells ﬁve times higher as much as the inoculums size required
for tumor induction.39 Our results clearly showed that vacci-
nation with pre-inactivated CT26 cells could effectively con-
fer protection against the same tumor. In our study, we
observed strong anti-tumor cellular responses after vaccina-
tion with either hAECs or CT26 exempliﬁed by a signiﬁ-
cantly higher frequency of peripheral blood and spleen T and
cytotoxic CD81 T cells which play a crucial role in anti-
tumor immunity.40 Interestingly, assessment of functional
CTL activity revealed that immunization with hAECs
induced a robust CTL activity against CT26 cells at all T:E
ratios tested and vice versa implying induction of anti-tumor
CTL responses by antigens shared by hAECs and CT26 cells.
It is possible that antigens expressed by hAECs cells are
cross-presented by mouse MHC molecules and activate
CD41 and CD81 cells. To determine whether such cross-
protection capability of hAECs is conﬁned to the colon ade-
nocarcinoma, we also tested anti-tumor vaccination potential
of hAECs in breast cancer and melanoma models. We
observed that hAECs vaccination had no obvious effect in
inhibiting 4T1 breast cancer cell growth, while signiﬁcantly
increased survival and prohibited tumor growth in a mice
model of melanoma. These results clearly indicated that anti-
tumor vaccination potential of hAECs is cancer type-
dependent. It remains to be determined which mechanisms
are responsible for such differential protective effect of
hAECs against cancers from histologically different origins.
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In parallel, sera from hAECs-vaccinated mice and rabbits
sharply recognized yet uncharacterized common surface
markers in CT26 and hAECs. In support of our ﬁndings, sev-
eral other investigators reported cross-reactive antibodies
directed against ovary (NuTu-19 Cells)41 and colon (CT26
Cells)17 cancer cells after immunization of mice with embry-
onic stem cells. In contrast, we found minimal or no cross-
reactive antibody responses in hAECs-vaccinated BALB/c or
C57BL/6 mice against 4T1 and B16F10 cells, respectively.
These results may indicate that hAECs antigens leading to
the induction of cross-reactive antibodies are not shared by
all cancer cell types.
The nature of such antigen(s) remain to be elucidated,
however, oncofetal antigens are most likely to be the target
antigens in induction of cross-protective immunity. Nonethe-
less, epitope spreading after hAECs-induced immune elimina-
tion of CT26 cells could also potentially lead to immune
responses against antigenic targets in CT26 cells not
expressed by hAECs cells.42 We do not think that hAECs-
induced anti-tumor immunity is due to a non-speciﬁc xeno-
geneic response as iPS cells from human origin (TZ1) was
shown to fail to inhibit tumor growth in the same model of
murine colon carcinoma.17 Indeed, our results showed that
anti-AEC hyper immune serum exhibit reactivity only with
small proportion of other mouse-derived cell lines, 4T1 and
Renca, or showed no reactivity at all with B16F10 melanoma
cells ruling out the possibility of non-speciﬁc xenogeneic
responses after hAECs immunization.
Although immune responses against antigens shared by
hAECs and CT26 cells seems to be a fascinating explanation
for hAECs-triggered resistance to colon cancer development,
direct anti-tumor properties of hAECs could be regarded as a
further explanation as reported by Kang et al.43 Anti-
angiogenic and -proliferative potential of hAECs are among
further well-characterized anti-cancer capacity of this cell
type44 which are also employed by amniotic membrane inner
cell population, amniotic mesenchymal cells.45 To investigate
further mechanisms responsible for immunity against tumor
establishment after hAECs vaccination, we next measured
cytokine levels produced by the peripheral blood and splenic
mononuclear cells. Our results showed that akin to mice
immunized with CT26, mice received hAECs prophylactic
vaccine produced a mixed pattern of cytokines attributed to
Th1, Th2 and regulatory T cells. Considering that speciﬁc
activity of different cytokines differs profoundly in essence
and is also affected by the experiment condition, we could
not come to a net conclusion that which cytokine proﬁle pre-
vails after vaccination with hAECs. Indeed, mechanisms
responsible for immunity against cancers are so complex that
no single immunological mechanism could certainly be
ascribed to tumor rejection. It should be noted that consider-
able amounts of cytokines were produced without stimulation
by splenocytes of hAECs- or CT26-vaccinated mice in vitro.
This pattern could be attributed to the continuation of
immunological responses initiated after vaccination as such
pattern was not observed in the control mice.
At present, it is not clear for us how long protective
immunity against cancer after hAECs vaccination lasts and
additional follow up studies are needed to be performed, but
such immunity would most likely wane over time46 necessi-
tating regular strengthening of memory responses.
Besides effectiveness of hAECs cells as a prophylactic cancer
vaccine, we were also interested to know to what extent immu-
nization with this cell type could be effective against a pre-
established tumor. Our results showed that when injected to the
tumor-bearing mice, hAECs considerably reduced tumor bur-
den. Although, treatment of tumor-bearing mice with hAECs
resulted in an increased frequency of T and CD81 T cells in
blood and spleen, not surprisingly CTL activity against cancer
cells was not affected. This ﬁnding is in line with previous
reports indicating that tumor progression in experimental mod-
els and in humans is associated with a functional impairment
in cancer antigen-speciﬁc CD81 T cells.47 Lyman et al. clearly
showed that cancer antigen-speciﬁc CTLs did not mount an
effector function in case of increasing tumor burden and tumor
antigen availability.48 In another study, despite presence of
CD81 T cells displaying an antigen-experienced phenotype in
regional draining lymph nodes, these cells were typically deﬁ-
cient in one or more effector functions; a phenomenon termed
“split anergy”.49 Interestingly, CTL activity against hAECs was
increased in hAECs-treated tumor-bearing mice indicating that
induction of CTL tolerance to tumor antigens in the course of a
cancer is fundamentally cancer stage-dependent. Nonetheless,
increased IFN-g and decreased IL-10 production by spleen cells
of hAECs-treated mice in response to CT26 stimulation could
be viewed as one possible mechanism responsible for induction
of Th1 immunity and reduction of tumor load, although there
might be other mechanisms and factors involved.
One main question that needs to be addressed is why
hAECs-vaccination confers protection against colon cancer
development while the same cells are only partially effective
in reduction of tumor burden when the cancer is established?
It can be postulated that pre-existing immunity against can-
cer cells might serve as a safe guard hindering proliferation
of cancer cells by induction of cell cycle arrest and apoptosis.
In this context, cancer cells do not ﬁnd an opportunity to
propagate and organize into a tumor. In contrast, the ability
of pre-established tumor to foster a tolerant microenviron-
ment and activation of a plethora of immunosuppressive
mechanisms47 prevents hAECs-induced anti-tumor responses
to be fully effective. In fact, quality of interaction between
tumor cells and the immune system is markedly a function
of time elapsed after initiation of carcinogenesis. In the very
early stages, most of the cancer cells are eliminated by well-
deﬁned immune surveillance mechanisms. However, when
tumor is established, growing cancer cells enhance their self-
protection via multiple immune evasion mechanisms and
anti-cancer immunity induced by therapeutic vaccination is
unable to exert full spectrum of anti-oncogenic activity.50 In
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support of this notion, Dong et al. demonstrated that admin-
istration of ESCs ﬁve days after inoculation of lung carci-
noma cells was signiﬁcantly less effective in tumor size
reduction compared to when mice were immunized with
these cells two days after tumor challenge.18
In conclusion, the results of our study clearly demon-
strated that hAECs possess the potential for being used as an
effective prophylactic vaccine for immune prevention of
colon cancer most probably due to the shared antigenic
determinants. The nature of protective antigens responsible
for tumor rejection, capacity of hAECs to confer protection
against other cancer types and assessment of cancer preven-
tive efﬁcacy of puriﬁed candidate hAECs antigens warrants
further investigations before hAECs-based prophylactic can-
cer vaccines move into clinical trials.
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